Stereotactic ablative radiotherapy for non-small cell lung cancer: Rationale and outcomes

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Stereotactic ablative radiotherapy (SABR), also known in older reports as stereotactic body radiation therapy, represents an evolving and expanding radiation treatment option for many forms of local malignancy, from primary tumors to metastatic and recurrent disease. It involves the precise delivery of higher doses of external-beam radiation per treatment over a shortened treatment course compared with traditional regimens. SABR has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and is becoming a more viable option for surgical candidates with early-stage primary NSCLCs who prefer noninvasive modalities of treatment. Although SABR is being used for the treatment of primary and metastatic disease in many sites of the body, such as the central nervous system, liver, pancreas, spine metastases, and isolated nodal disease in the mediastinum and abdomen, this article focuses on treatment of NSCLC in the thorax. Specifically, this review provides the rationale, evidence, and indications for treating early-stage lung cancers with SABR.

Original languageEnglish (US)
Pages (from-to)1514-1520
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number12
StatePublished - Dec 1 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Radiation
Mediastinum
Standard of Care
Abdomen
Pancreas
Lung Neoplasms
Neoplasms
Spine
Thorax
Central Nervous System
Neoplasm Metastasis
Liver

ASJC Scopus subject areas

  • Oncology

Cite this

@article{04f5254635d94212b6ce28b5ae4b4e0a,
title = "Stereotactic ablative radiotherapy for non-small cell lung cancer: Rationale and outcomes",
abstract = "Stereotactic ablative radiotherapy (SABR), also known in older reports as stereotactic body radiation therapy, represents an evolving and expanding radiation treatment option for many forms of local malignancy, from primary tumors to metastatic and recurrent disease. It involves the precise delivery of higher doses of external-beam radiation per treatment over a shortened treatment course compared with traditional regimens. SABR has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and is becoming a more viable option for surgical candidates with early-stage primary NSCLCs who prefer noninvasive modalities of treatment. Although SABR is being used for the treatment of primary and metastatic disease in many sites of the body, such as the central nervous system, liver, pancreas, spine metastases, and isolated nodal disease in the mediastinum and abdomen, this article focuses on treatment of NSCLC in the thorax. Specifically, this review provides the rationale, evidence, and indications for treating early-stage lung cancers with SABR.",
author = "Puneeth Iyengar and Timmerman, {Robert D.}",
year = "2012",
month = "12",
day = "1",
language = "English (US)",
volume = "10",
pages = "1514--1520",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",

}

TY - JOUR

T1 - Stereotactic ablative radiotherapy for non-small cell lung cancer

T2 - Rationale and outcomes

AU - Iyengar, Puneeth

AU - Timmerman, Robert D.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Stereotactic ablative radiotherapy (SABR), also known in older reports as stereotactic body radiation therapy, represents an evolving and expanding radiation treatment option for many forms of local malignancy, from primary tumors to metastatic and recurrent disease. It involves the precise delivery of higher doses of external-beam radiation per treatment over a shortened treatment course compared with traditional regimens. SABR has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and is becoming a more viable option for surgical candidates with early-stage primary NSCLCs who prefer noninvasive modalities of treatment. Although SABR is being used for the treatment of primary and metastatic disease in many sites of the body, such as the central nervous system, liver, pancreas, spine metastases, and isolated nodal disease in the mediastinum and abdomen, this article focuses on treatment of NSCLC in the thorax. Specifically, this review provides the rationale, evidence, and indications for treating early-stage lung cancers with SABR.

AB - Stereotactic ablative radiotherapy (SABR), also known in older reports as stereotactic body radiation therapy, represents an evolving and expanding radiation treatment option for many forms of local malignancy, from primary tumors to metastatic and recurrent disease. It involves the precise delivery of higher doses of external-beam radiation per treatment over a shortened treatment course compared with traditional regimens. SABR has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and is becoming a more viable option for surgical candidates with early-stage primary NSCLCs who prefer noninvasive modalities of treatment. Although SABR is being used for the treatment of primary and metastatic disease in many sites of the body, such as the central nervous system, liver, pancreas, spine metastases, and isolated nodal disease in the mediastinum and abdomen, this article focuses on treatment of NSCLC in the thorax. Specifically, this review provides the rationale, evidence, and indications for treating early-stage lung cancers with SABR.

UR - http://www.scopus.com/inward/record.url?scp=84871425894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871425894&partnerID=8YFLogxK

M3 - Article

C2 - 23221789

AN - SCOPUS:84871425894

VL - 10

SP - 1514

EP - 1520

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 12

ER -